Empowering phase II clinical trials to reduce phase III failures.

Area of Science:

• Clinical Trials
• Pharmaceutical Research
• Biostatistics

Background:

• Phase III clinical trials exhibit a high failure rate of approximately 45%.
• Failures can stem from various factors, including lack of efficacy and suboptimal treatment profiles.
• Existing literature suggests generic improvements but doesn't fully address the root causes.

Purpose of the Study:

• To numerically describe and analyze the phenomenon of phase III clinical trial failures.
• To identify the primary reasons contributing to these failures.
• To evaluate potential countermeasures, focusing on phase II trial expansion and alternative strategies.

Main Methods:

• Numerical description of failure rates in phase III trials.
• Review of literature for suggested improvements and reasons for failure.
• Economic profile analysis for phase II trial enlargement.
• Discussion of alternative strategies like biomarker enrichment and adaptive designs.

Main Results:

• Statistics explain, but do not justify, the high failure rate.
• At least 10% of failures are due to unexpected lack of efficacy.
• Expanding phase II is identified as a simple, intuitive method to reduce phase III failures.
• Alternative strategies have low current application rates.

Conclusions:

• Expanding phase II trials can mitigate false negatives and suboptimal treatment launches in phase III.
• Phase II enlargement requires case-by-case economic evaluation due to limited research resources.
• While alternative strategies exist, their adoption is slow, highlighting the need for practical solutions like phase II enhancement.